$IONS News and Market Events
Every $IONS story Market Flux has tracked.
- Top Story
European Drug Panel Backs Ionis Triglyceride Drug and Lilly Weight-Loss Pill While Rejecting Omeros Transplant Therapy
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a series of regulatory decisions on Friday, approving several treatments and definitively closing the…
- Market Flux Event
European Drug Panel Backs Ionis Triglyceride Drug and Lilly Weight-Loss Pill While Rejecting Omeros Transplant Therapy
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a series of regulatory decisions on Friday, approving several treatments and definitively closing the…
- Unusual Volume
Novartis Shares Crash 14% to 52-Week Low After Three Drug Trial Failures in One Week
Novartis suffered a devastating session on Tuesday, September 8, with its U.S.-listed shares tumbling roughly 14% to close at $137.70, a fresh 52-week low, after two major late-stage…
- Top Mover
Amgen Plunges 10% as Novartis Lp(a) Trial Failure Casts Doubt on Olpasiran Program
Amgen shares fell roughly 10% on Tuesday, putting the stock on course for its worst single-day decline since 2000, after Novartis reported that its Lp(a)-lowering drug pelacarsen failed in…
- Market Flux Event
Novartis and Ionis Heart Drug Pelacarsen Fails Phase 3 Trial, Sending Shares Lower
Pelacarsen, a drug developed by Novartis and partner Ionis Pharmaceuticals to lower lipoprotein(a), or Lp(a), failed to reduce the risk of cardiovascular events in a late-stage clinical…